{
  "guideline": {
    "id": "PA166105213",
    "name": "Annotation of FDA Label for oxcarbazepine and HLA-B",
    "objCls": "Label Annotation",
    "source": "FDA",
    "version": 31,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166105213",
    "relatedChemicals": [
      {
        "id": "PA450732",
        "name": "oxcarbazepine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166310841",
      "name": "Recommendation Annotation PA166310841",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450732",
          "name": "oxcarbazepine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452213280,
        "html": "<p>&quot;The use of oxcarbazepine should be avoided in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product OXTELLAR XR (OXCARBAZEPINE), NDA202810, Supernus Pharmaceuticals, Inc.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202810"
    }
  ],
  "version": "2024-03-08-14-34"
}